METABOLIC PHENOTYPING, LIPIDOMICS & BIOINFORMATICS IN DEMENTIA
With
Dr Luke Whiley
Curtin Medical Research Institute,
Western Australia
RESEARCHER PROFILE
Filmed in Perth, Western Australia | February 2026
Dr Luke Whiley is a dementia researcher whose work focuses on understanding how the body’s metabolism, particularly the biology of fats known as lipids, influences our health throughout ageing.
His research explores how the body responds to illness, lifestyle, and environmental stress at a chemical level, and how these responses shape longterm disease risk. Using advanced blood-based measurement technologies, Dr Whiley studies thousands of small molecules at once to build a snapshot of a person’s metabolic health. By combining these measurements with data science approaches, his work identifies biological pathways that become disrupted in disease, providing insight into why some people are more vulnerable to conditions such as dementia.
A major focus of Dr Whiley’s research is Alzheimer’s disease, where he investigates how genetic risk, particularly variations in genes involved in lipid transport, may affect metabolism across the body and lead to disease. This work highlights the importance of lipids in brain health, helping shift dementia research beyond proteins alone to include broader metabolic processes.
He also studies related questions in Parkinson’s disease, traumatic brain injury, and COVID19, where metabolic disruption plays a key role in recovery and longterm outcomes. Alongside discovery research, Dr Whiley develops methods that allow detailed metabolic testing using much smaller samples, making future screening and monitoring more accessible.
His overarching goal is to improve understanding, earlier detection, and prevention of neurodegenerative disease, while keeping people with lived experience at the centre of dementia research.
Source: Supplied
https://orcid.org/0000-0002-9088-4799
-
Clinical guidelines for diagnostics and early intervention in Primary Aldosteronism
Primary Aldosteronism (PA), or Conn Syndrome, is the most commonly under-diagnosed cause of high blood pressure affecting millions of people. Associate Professor Jun Yang’s goal is to facilitate the diagnosis of every case of PA and make treatment widely available to all communities including the disadvantaged.
-
Neonatal respiratory trials in sick & preterm newborn infants
Prof Brett J. Manley leads and collaborates on large national and international randomised clinical trials in neonatology. He previously collaborated on 4 randomised trials of nasal high-flow as non-invasive respiratory support for preterm and term infants, all of which were published in N Engl J Med. Recently he led the PLUSS trial of intratracheal budesonide for extremely preterm infants, that recruited in 21 NICUs across 4 countries, the results of which were published in JAMA. PLUSS was awarded the Australian Clinical Trials Alliance Trial of the Year in 2025. Another passion of his is mentoring and supervising early career researchers to undertake their own clinical trials.
-
Mechanisms of resistance to menin inhibitor therapy and Acute Myeloid Leukaemia
Dr Rithin Nedumannil (MBBS, MPH, FRACP, FRCPA) is a PhD candidate at the University of Melbourne, undertaking his doctoral studies in collaboration with the Cambridge Stem Cell Institute (Cambridge, UK) and the Peter MacCallum Cancer Centre (Melbourne, Australia). He is a clinical haematologist and haematopathologist with current appointments at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, Austin Health and Northern Health.
